|
May 4
|
23 Most Profitable Stocks of the Last 12 Months
|
|
May 3
|
Insider Sale at Vertex Pharmaceuticals Inc (VRTX): Director Sangeeta Bhatia Sells Shares
|
|
May 2
|
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
|
|
May 2
|
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
|
|
May 1
|
Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know
|
|
May 1
|
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
|
|
Apr 30
|
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
|
|
Apr 11
|
Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal
|
|
Apr 11
|
Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It
|
|
Apr 11
|
Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands
|
|
Apr 11
|
Vertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street Says.
|
|
Apr 11
|
Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised
|
|
Apr 11
|
These Stocks Are Moving the Most Today
|
|
Apr 11
|
Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer
|
|
Apr 11
|
Vertex Pharmaceuticals: Buy, Sell, or Hold?
|
|
Apr 11
|
US STOCKS-Futures slip as rate-cut hopes ebb
|
|
Apr 10
|
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
|
|
Apr 10
|
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion
|
|
Apr 10
|
Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal
|
|
Apr 10
|
UPDATE 3-Vertex Pharma bets on kidney disease treatment with $4.9 bln Alpine Immune deal
|